Regulation of Presynaptic Neurotransmission by Macroautophagy  by Hernandez, Daniela et al.
Neuron
ReportRegulation of Presynaptic Neurotransmission
by Macroautophagy
Daniela Hernandez,1,6 Ciara A. Torres,2,6 Wanda Setlik,3 Carolina Cebria´n,4 Eugene V. Mosharov,4 Guomei Tang,4
Hsiao-Chun Cheng,4 Nikolai Kholodilov,4 Olga Yarygina,4 Robert E. Burke,4 Michael Gershon,3 and David Sulzer4,5,*
1Department of Neuroscience
2Integrated Program in Cellular, Molecular, and Biomedical Studies
3Department of Pathology
4Department of Neurology
5Department of Psychiatry and Pharmacology
Columbia University Medical Campus, New York, NY 10013, USA
6These authors contributed equally to this work
*Correspondence: ds43@columbia.edu
DOI 10.1016/j.neuron.2012.02.020SUMMARY
mTOR is a regulator of cell growth and survival,
protein synthesis-dependent synaptic plasticity,
and autophagic degradation of cellular components.
When triggered bymTOR inactivation,macroautoph-
agy degrades long-lived proteins and organelles
via sequestration into autophagic vacuoles. mTOR
further regulates synaptic plasticity, and neurode-
generation occurs when macroautophagy is defi-
cient. It is nevertheless unknown whether macroau-
tophagy modulates presynaptic function. We find
that themTOR inhibitor rapamycin induces formation
of autophagic vacuoles in prejunctional dopami-
nergic axons with associated decreased axonal
profile volumes, synaptic vesicle numbers, and
evoked dopamine release. Evoked dopamine secre-
tion was enhanced and recovery was accelerated
in transgenic mice in which macroautophagy defi-
ciency was restricted to dopaminergic neurons;
rapamycin failed to decrease evoked dopamine
release in the striatum of these mice. Macroautoph-
agy that follows mTOR inhibition in presynaptic
terminals, therefore, rapidly alters presynaptic struc-
ture and neurotransmission.
INTRODUCTION
The kinase mammalian target of rapamycin (mTOR) regulates
protein synthesis (Huang and Manning, 2009) and degradation
(Cuervo, 2004). mTOR activity enhances protein synthesis via
participation in the complex mTORC1, which phosphorylates
S6, S6 kinase, and 4E-BP (Huang andManning, 2009). mTORC1
also phosphorylates Atg13, inhibiting Atg1, which is required for
the induction of macroautophagy (Kamada et al., 2010). mTOR
activity, therefore, both enhances protein synthesis and inhibits
cellular degradation pathways.In the nervous system, mTORC1 activity stimulates protein
synthesis-dependent synaptic plasticity and learning (Huang
and Manning, 2009; Long et al., 2004; Richter and Klann, 2009).
Most studies on cellular and neuronal functions of mTOR use
rapamycin, an inhibitor that, when bound to FKBP12, interacts
with mTOR’s FRB domain and prevents mTOR from binding
raptor, a component of the mTORC1 complex (Dowling et al.,
2010). Rapamycin blocks axonal hyperexcitability and synaptic
plasticity in cellular models of injury, as well as learning and
memory, by inhibiting protein synthesis (Hu et al., 2007; Wera-
goda and Walters, 2007).
Macroautophagy is a highly conserved cellular degradative
process in which proteins and organelles are engulfed by auto-
phagic vacuoles (AVs) that are subsequently targeted for degra-
dation in lysosomes. It is possible that degradation of pre- or
postsynaptic components could contribute to plasticity: for
example, local mTOR inhibition might elicit autophagic degrada-
tion of synaptic vesicles, providing a means of presynaptic
depression. We therefore explored whether mTOR-regulated
degradation of proteins and organelles via macroautophagy
alters synaptic function and morphology.
To do so, we generated transgenic mice in which macroau-
tophagy was selectively inactivated in dopamine neurons. These
neurons are deficient in expression of Atg7, an E1-like enzyme
that conjugates microtubule-associated protein light chain 3
(LC3) tophospholipid andAtg5 toAtg12, steps that are necessary
for AV formation (Martinez-Vicente and Cuervo, 2007). We chose
to specifically delete Atg7 to abolish macroautophagy and the
formation of AVs because, in contrast to Atg1, it is not thought
to directly regulate membrane trafficking (Wairkar et al., 2009).
We chose to examine presynaptic structure and function in
the dopamine system because (1) in the acute striatal slice
preparation, dopamine axons are severed from their cell bodies
but continue to synthesize, release, and reaccumulate neuro-
transmitter for up to 10 hr, allowing us to clearly focus on axonal
autophagy, and (2) electrochemical recordings of evoked dopa-
mine release and reuptake in the striatum provide a unique
means to measure central nervous system (CNS) neurotrans-
mission with millisecond resolution that is independent of
postsynaptic response.Neuron 74, 277–284, April 26, 2012 ª2012 Elsevier Inc. 277
Figure 1. Macroautophagy Deficiency Results in
Morphological Alterations In Vivo
Dopaminergic striatal axonal projections from 8-week-old
male mice were identified by TH immunolabel. (A) Repre-
sentative electron micrographs in DAT Cre and Atg7 DAT
Cre mice. Arrowheads indicate TH+ axonal profiles. Scale
bars represent 500 nm. (B) There was no difference in the
number of TH+ profiles/100 mm2 between DAT Cre and
Atg7 DAT Cre mice (p > 0.05; t test). (C) The total area
occupied by TH+ profiles in striatum from Atg7 DAT Cre
was larger than in DAT Cre mice (p < 0.05; two-tailed
t test). (D) The average area of TH+ profiles was 45% larger
in Atg7 DAT Cre (n = 84) than DAT Cre (n = 61) (p < 0.05;
t test). (E) There was no significant difference in the size of
TH profiles between DAT Cre (n = 26) and Atg7 DAT Cre
(n = 27) mice (p > 0.05; t test). (F) Rapamycin in vivo
(administered twice, 36 and 12 hr prior to sacrifice)
decreased TH+ profiles by 32% in DAT Cre mice (n = 51,
DMSO; n = 54, rapamycin), but not in Atg7 DAT Cre mice
(n = 116, DMSO; n = 61, rapamycin; interaction between
rapamycin and genotype, F = 6.72; p < 0.01; two-way
ANOVA). Error bars indicate SEM.
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Presynaptic MacroautophagyWe found that (1) chronic macroautophagy deficiency in
dopamine neurons resulted in increased size of axon profiles,
increased evoked dopamine release, and more rapid pre-
synaptic recovery; (2) in mice with intact macroautophagy,
mTOR inhibition with rapamycin acutely increased AV forma-
tion in axons, decreased the number of synaptic vesicles,
and depressed evoked dopamine release; and (3) rapamycin
had no effect on evoked dopamine release and synaptic
vesicles in dopamine neuron-specific macroautophagy-defi-
cient mice. We conclude that mTOR-dependent local axonal
macroautophagy can rapidly regulate presynaptic structure
and function.
RESULTS
Dopamine Neuron-Specific Autophagy-Deficient Mice
We generated dopamine neuron-specific macroautophagy-
deficient mice by crossing Atg7flox/flox mice (Komatsu et al.,
2005) to a line expressing Cre recombinase under the dopamine
transporter (DAT) promoter (DAT Cre/+) (Zhuang et al., 2005).
The progeny (Atg7flox/+;DAT Cre/+) were crossed to Atg7flox/flox
to generate Atg7flox/flox;DAT Cre/+ (Atg7 DAT Cre). Because
the mutant mice have a single functional copy of DAT, we used
DAT Cre/+ (DAT Cre) animals as controls; these animals express
two copies of wild-typeAtg7 and a single functional copy ofDAT.
We detected Atg7 expression by nonradioactive in situ
hybridization using an RNA probe designed against nucleotides
1518–1860 of the Atg7 gene in 8- to 10-week-old mice. Atg7278 Neuron 74, 277–284, April 26, 2012 ª2012 Elsevier Inc.mRNA was detected in both the anterior and
central substantia nigra pars compacta and
pars reticulata in DAT Cre animals but was
absent in Atg7 DAT Cre mice. Atg7 mRNA was
detected in the red nucleus (RN) and in the
dentate gyrus (DG) from Atg7 DAT Cre, further
indicating cellular specificity for the knocked
out gene (see Figure S1 available online). Weconclude that the Atg7 gene was effectively deleted in ventral
midbrain dopamine neurons.
In contrast to CNS-wide macroautophagy-deficient mice,
which are smaller than controls, exhibit abnormal limb clasping,
and begin to die at 4 weeks (Hara et al., 2006; Komatsu et al.,
2006), Atg7 DAT Cre mice showed similar survival and weight
gain as DAT Cre mice at 8 weeks of age (mean weights: 22.7 ±
1.1 g and 25.2 ± 1.6 g, respectively; p > 0.05; n = 6 mice per
group; t test). The limb-clasping reflex of Atg7 DAT Cre mice
was normal (data not shown). To evaluatemotor behavior in tasks
thought to specifically involve dopamine transmission (Crawley,
1999; Karl et al., 2003), we performed tail-hang, beam-walk,
and open-field tests on mice aged 6–12 weeks. Motor perfor-
mances of Atg7 DAT Cre mice were not different than DAT Cre
in any of the tests (n = 4 in each group; data not shown). We
did not examine mice older than 3 months in this study, and
motor and behavioral differences may develop in aged mice.
Dopaminergic Axonal Profiles Are Larger
in the Autophagy-Deficient Mice
We examined striatal dopaminergic axonal profiles immunola-
beled for tyrosine hydroxylase (TH) from 8-week-old DAT Cre
and Atg7 DAT Cre mice by electron microscopy (Figure 1A).
There was no difference in the number of striatal TH immu-
noreactive axonal profiles per area in Atg7 DAT Cre mice (Fig-
ure 1B). There was, however, an increase in the fraction of total
area occupied by TH+ profiles: TH+ axon profiles occupied
2.3% ± 0.2% of the total sampled area in the striatum of DAT
Figure 2. Evoked Dopamine Release in Atg7 DAT
Cre Mice
(A) Cyclic voltammetry recordings of evoked dopamine
release from slices of dorsal striatum from DAT Cre and
Atg7 DAT Cre mice. (B) Evoked DA release was higher in
Atg7 DAT Cre mice than in DAT Cre controls (p < 0.005; t
test). There was no difference in the half-life (t1/2) of the
DA signals from DAT Cre and Atg7 DAT Cre (Figure S2).
(C) Representative traces from paired-pulse recordings at
interstimulus intervals of 5–60 s from a DAT Cre and Atg7
DAT Cre slice (slightly offset to aid comparison). (D)
Paired-pulse ratio at interstimulus intervals of 1–60 s
(mean ± SEM). Atg7 DAT Cre recovery was faster than
DAT Cre controls (p < 0.05; repeated-measures ANOVA).
(E) Representative traces from control (DMSO vehicle) and
rapamycin-treated (red) DAT Cre and Atg7 DAT Cre slices.
(F) Rapamycin decreased the peak amplitude of dopa-
mine signals in DAT Cre striata by 25% ± 3% but
decreased it by only 6% ± 6% in Atg7 DAT Cre striata (p <
0.05; two-way ANOVA). Rapamycin had no effect on the
signal t1/2 (Figure S2). Error bars indicate SEM.
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0.005; t test; >6,000 mm2 sampled per condition in ten and eight
micrographs, respectively; Figure 1C). Consistently, striatal TH+
axonal profiles from Atg7 DAT Cre mice (0.42 ± 0.04 mm2, n = 84)
were larger than profiles from DAT Cre animals (0.29 ± 0.03 mm2,
n = 60; p < 0.05; Mann-Whitney test; Figure 1D). We found no
difference in the size of terminals unlabeled for TH between
DAT Cre and Atg7 DAT Cre mice (0.24 ± 0.03 mm2, n = 26;
0.30 ± 0.03 mm2, n = 27; p > 0.05; t test; Figure 1E).
To explore the effects ofmTOR inhibition andmacroautophagy
deficiency on the size of dopamine axonal profiles, we injected
pairs ofDATCreandAtg7DATCremicewith rapamycin (2mg/kg)
or vehicle (DMSO) 36 and 12 hr prior to perfusion. Rapamycin
decreased the area of TH+ striatal axon profiles by 32% in DAT
Cre mice but had no effect on DA terminals of the DAT Cre Atg7
mutant line (Figure 1F) (interaction between rapamycin and geno-
type, F = 6.72; p < 0.01; two-way analysis of variance [ANOVA]).
Dopamine Neurotransmission in Atg7 DAT Cre Mice
We used cyclic voltammetry to directly measure evoked dopa-
mine release and reuptake in the striatum. The peak amplitudeNeuron 74of the signal is dependent on both neurosecre-
tion and reuptake through DAT, whereas the
half-life (t1/2) is a function of DAT activity
(Schmitz et al., 2001).
The amplitude of the dopamine signal
evoked by a single pulse of electrical stimula-
tion in Atg7 DAT Cre mice was 54% greater
than in DAT Cre controls (n = 9 and n = 7,
respectively; 4.0 ± 0.3 and 2.6 ± 0.2 nM,
respectively; p < 0.005; t test; Figures 2A and
2B). As DAT Cre and Atg7 DAT Cre mice
express a single functional copy of DAT, the
signal duration in both genotypes was longer
than in wild-type mice (mean t1/2: 490 ms)
(Schmitz et al., 2001), but the mean t1/2 ofDAT signals from DAT Cre and Atg7 DAT Cre slices was not
different (Figure S2A; mean t1/2: 637 ± 51 and 662 ± 23 ms,
respectively; p > 0.05; t test), which indicates that reuptake
kinetics are similar and that the increased peak amplitude in
the Atg7-deficient line was due to greater dopamine release
rather than decreased reuptake.
To measure the rate of presynaptic recovery, we stimulated
dopamine release with pairs of pulses separated by intervals
that ranged from 1 to 60 s (Schmitz et al., 2002). Atg7 DAT Cre
mice exhibited faster recovery (p < 0.05; repeated-measures
ANOVA; Figure 2D), suggesting that basal macroautophagy
can restrict synaptic transmission.
We then examined effects of rapamycin on evoked dopamine
release. Striatal slices were bisected, and one striatum was
exposed to rapamycin (3 mM, >5.5 hr)and the other to vehicle.
Rapamycin decreased dopamine release evoked by a single
electrical stimulus by 25% ± 3% in DAT Cre slices (n = 7) and
by 6% ± 6% in Atg7 DAT Cre slices (n = 9; p < 0.05; two-way
ANOVA; Newman-Keuls posttest; Figures 2E and 2F). Rapamy-
cin did not significantly alter the t1/2 of the signals from DAT Cre
(control: 718 ± 29 ms; Rapa: 675 ± 22 ms) or Atg7 DAT Cre, 277–284, April 26, 2012 ª2012 Elsevier Inc. 279
Figure 3. Rapamycin Effects on LC3 in VM DA
Neurons
(A) Somatodendritic regions of dopaminergic neurons
(TH+, red immunolabel) derived from wild-type (WT) and
DAT Cre mice exposed to rapamycin (RAPA, 3 mM, 3.5 hr)
exhibited an increased number of LC3+ puncta (green
immunolabel, examples indicated by white arrowheads)
compared to dopaminergic neurons treated with vehicle
(DMSO). There was no induction of LC3+ puncta by
rapamycin in DA neurons from Atg7 DAT Cre mice. Scale
bar represents 10 mm. (B) Similar results were observed
throughout neurites. Rapamycin increased LC3 puncta
(white arrows) in TH+ neurites, but not in Atg7-deficient
dopaminergic neurites. Scale bar represents 4 mm. (C)
Number of LC3+ puncta per TH+ neuron (cell bodies and
neurites) for these conditions (mean ± SEM; n = 3 exper-
imental repeats, 30 neurons rated per experiment per
condition; t test; ns, nonsignificant; **p < 0.01). (D) Rapa-
mycin at 3.5 hr increased LC3-II by 56% (n = 3; p < 0.001;
two-way ANOVA) but had no effect at 7 hr, indicating
a temporary induction of LC-II in the slice preparation
consistent with turnover of AVs. Error bars indicate SEM.
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p > 0.05; two-way ANOVA).
The data indicate that the bulk of rapamycin’s inhibition of
evoked dopamine release is mediated by macroautophagy. To
confirm that these effects were not limited to DAT Cre mutants,
we repeated the recordings in slices from wild-type mice and
observed a similar rapamycin-induced reduction in dopamine
secretion (Figure S2B).
Effects of Acute Rapamycin Treatment
To examine the effect of acute mTOR inhibition on AV formation,
we first exposed postnatally derived ventral midbrain neuronal
cultures (Rayport et al., 1992) to rapamycin (200 nM, 3.5 hr).
The macroautophagy-related protein LC3 exists in two forms,
LC3-I and LC3-II, a phosphatidylethanolamine-conjugated
form of LC3-I. LC3-I is widely distributed in the cytosol, whereas
the conjugated LC3-II form specifically associates with AV
membranes (Mizushima et al., 2004). Dopamine neurons were
identified by TH immunolabel, and immunolabel for native LC3
was used to identify AVs. There were occasional LC3-immunola-
beled puncta in the Atg7-deficient cell bodies and neurites,
possibly due to noncanonical AV formation (Nishida et al.,
2009). Rapamycin strikingly increased LC3-immunolabeled
puncta in dopamine cell bodies and neurites in DAT Cre mice280 Neuron 74, 277–284, April 26, 2012 ª2012 Elsevier Inc.but had no effect on puncta in DAT Cre Atg7
mutants (p < 0.01; ANOVA) (Figures 3A–3C),
showing that induction of AVs by rapamycin
required Atg7 expression.
We then examined the induction of LC3-II
by rapamycin (3 mM) in acute striatal slices by
western blotting. Rapamycin at 3.5 hr produced
a 56% increase in LC3-II (Figure 3D) (p < 0.001;
t test), but this response was no longer apparent
at 7 hr, indicating that rapamycin induced a
transient increase of LC3-II, a characteristic of
macroautophagy.In electron micrographs of striatal slices, we identified AV-like
organelles based on previously described criteria (Yu et al.,
2004) as nonmitochondrial structures in presynaptic terminals
that possessed multiple membranes, usually with luminal
content. These organelles were different from multivesicular
bodies, organelles of the autophagic-lysosomal pathway that
typically displays an even distribution of vesicles in the lumen.
Many AV-like organelles contained a wide range of luminal
constituents, including small vesicles resembling synaptic vesi-
cles (compare Figures 4A and 4B). Somemultilamellar structures
were devoid of obvious luminal electron-dense material (Marti-
nez-Vicente et al., 2010), possibly due to acute induction of AVs
by rapamycin. It is likely that some of these multilamellar organ-
elles include endosomes or are ‘‘amphisomes’’ that result from
fusion of endosomes and AVs. Rapamycin in the striatal slice
more than doubled the number of presynaptic terminal profiles
containing AV-like structures from 15.4% of control terminal
profiles (n = 65) to 35.5% in rapamycin-treated terminals (n =
75; p < 0.05; chi-square test; Figure 4C) and decreased terminal
profile areas by 19% (p < 0.05; t test; Figure 4D). Striatal terminal
profiles from rapamycin-treated samples, of which only a small
fraction are dopaminergic, moreover contained fewer synaptic
vesicles than untreated controls (49.2 ± 3.6, n = 75 versus
70.1 ± 4.2, n = 65; p < 0.0001, respectively; t test; Figure 4E).
Figure 4. Acute mTOR Inhibition Induces Morpho-
logical Changes at Synaptic Terminal Profiles
(A and B) Electron micrographs from untreated cortico-
striatal slices (A) and rapamycin-treated corticostriatal
slices (3 mM, 7 hr) (B). Presynaptic terminal AV-like
organelles are marked by red arrowheads. Scale bars
represent 500 nm. (C) Rapamycin increased the fraction of
synaptic terminal profiles with AV-like organelles (p < 0.05;
chi-square). (D) Acute rapamycin decreased terminal
profile area (p < 0.05; t test). (E) Synaptic terminal profiles
from rapamycin-treated slices contained fewer synaptic
vesicles than untreated slices (p < 0.0001; t test). Error
bars indicate SEM.
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synaptic or postsynaptic densities (Nirenberg et al., 1997), but
amperometric studies demonstrate stimulation-evoked quantal
transmitter release from these structures (Pothos et al., 1998),
and many accumulate and secrete fluorescent dopamine
analogs (Gubernator et al., 2009), confirming their identity as
presynaptic terminals. Because TH immunolabel obscured
synaptic vesicles and other intracellular structures (see Figure 1),
we examined whether rapamycin reduced the number of dopa-
minergic synaptic vesicles by using the false neurotransmitter
5-hydroxydopamine (5OHDA), which is selectively accumulated
into these dopaminergic synaptic vesicles and produces
osmophilic dense cores (Tennyson et al., 1974) (Figure 5, blue
arrows). For each experiment, striatal slices were obtained
from a single mouse, bisected, and individual striata were incu-
bated in vehicle (DMSO) or rapamycin (3 mM, 6.5 hr) and then
treated with 5OHDA (500 mM, 30 min). The numbers of synaptic
vesicles in the labeled terminals were compared between slices
derived from the same mouse. In a wild-type mouse, rapamycin
decreased synaptic vesicles within 5OHDA-labeled terminals by
18% (from 105 to 86 synaptic vesicles per mm2; p < 0.02; t test;Neuron 7437 and 42 terminals rated), and in a DAT Cre
mouse, rapamycin decreased synaptic vesicles
within labeled terminals by 26% (from 82 to 61
synaptic vesicles per mm2; p = 0.05; t test; 31
and 27 terminals rated). In contrast, rapamycin
did not decrease synaptic vesicles within
labeled terminals of an Atg7 DAT Cre mouse
(84 to 95 synaptic vesicles per mm2; p = 0.13; t
test; 38 and 39 terminals rated), indicating that
rapamycin decreased the number of dopami-
nergic synaptic vesicles only if Atg7 was
present.
We compared the levels of a range of synaptic
proteins between striatal slices of DAT Cre mice
and Atg7 DAT Cre mice exposed to rapamycin
(3 mM) or vehicle for 7 hr. Treated and untreated
Atg7 DAT Cre mice showed substantially lower
levels of DAT (Figure S3; Table S1), a small but
significant decrease of TH (p < 0.05; two-factor
ANOVA), similar levels (p > 0.5) of the postsyn-
aptic marker PSD95, and the mitochondrial
proteins porin, tomm20, and tim23. Althoughthere was a transient increase in LC3-II at 3.5 hr (Figure 3D), no
protein examined was altered by rapamycin at 7 hr. It may be
that although this period provided sequestration of cellular
elements in AVs, there was no measurable net degradation
over this period. Note that only axons of dopamine neurons
were present, and corresponding cell bodies with mature lyso-
somes were absent.
DISCUSSION
Our data indicate that both basal and induced macroautophagy
modulates presynaptic structure and function. Mice with chronic
macroautophagy deficiency in dopamine neurons had abnor-
mally large dopaminergic axonal profiles, released greater levels
of neurotransmitter in response to stimulation, and exhibited
more rapid presynaptic recovery. mTOR inhibition by rapamycin
administered to control mice induced AV-like structures in
axons and decreased synaptic vesicles to nearly the same
level as the accompanying decrease in evoked dopamine
release. In contrast, rapamycin had little or no effect on the
number of synaptic vesicles or neurotransmitter release in, 277–284, April 26, 2012 ª2012 Elsevier Inc. 281
Figure 5. Effects of Rapamycin on Synaptic Vesi-
cles in Terminals Labeled by the False Transmitter
5-Hydroxydopamine
For each experiment, slices from the same mouse were
compared. (A and B) Examples of synaptic terminals from
striatal slices from a wild-type mouse incubated with
vehicle (DMSO) for 6.5 hr and followed by 5-hydrox-
ydopamine (5OHDA) (500 mM) for 30 min. (C and D)
Examples of terminals in the striatal slice exposed to ra-
pamycin (3 mM, 6.5 hr) and followed by 5OHDA for 30 min.
Yellow arrows indicate examples of synaptic vesicles in
nondopaminergic terminals; blue arrows indicate labeled
dopaminergic synaptic vesicles; red arrow indicates
a structure that may be an isolation membrane. Scale bar
represents 100 nm. (E–G) Number of synaptic vesicles per
unit area (mm2) of 5OHDA-labeled terminals after exposure
to DMSO or rapamycin in wild-type (E), DAT Cre (F), or
Atg7 DAT Cre (G) striatal slices. *p < 0.05; t test. Error bars
indicate SEM.
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duce acute presynaptic changes that depend on Atg7 expres-
sion and hence macroautophagy.
These presynaptic effects were observed in dopaminergic
presynaptic terminals in slices without their cell bodies, and
so the critical steps in autophagy must have occurred locally
in axons that typically lack mature lysosomes (Overly et al.,
1995). Our data confirm that AVs can be synthesized locally
in the axons (Lee et al., 2011) and indicate that local axonal au-
tophagy can sequester presynaptic components and modulate
presynaptic function. This evidence extends studies of selec-
tive degradation of postsynaptic receptors via macroautophagy
(Hanley, 2010; Matsuda et al., 2008; Rowland et al., 2006) and
classic work indicating a role for lysosomal degradation in recy-
cling synaptic vesicle turnover (Holtzman et al., 1971). Thus, in
addition to well-established roles of macroautophagy in stress
response and cellular homeostasis (Tooze and Schiavo, 2008),
neurons have adapted this phylogenetically ancient process to
modulate neurotransmitter release and remodel synapses.
Chronic Macroautophagy Deficiency and Neuronal
Morphology
Macroautophagy deficiency throughout the CNS results in
decreased weight, motor deficits, and premature death (Hara
et al., 2006; Komatsu et al., 2006). Purkinje cells from cell-
specific autophagy-deficient mice show axonal swellings and
signs of neurodegeneration as early as postnatal day 19 (Ko-282 Neuron 74, 277–284, April 26, 2012 ª2012 Elsevier Inc.matsu et al., 2007). Signs of neurodegeneration
were, however, not observed in young DAT Cre
Atg7 mice (<14 weeks), possibly due to
compensation by other degradative pathways
(Koga et al., 2011). It may be that further aged
DAT Cre Atg7 mice model aspects of Parkin-
son’s-related disorders.
Chronic autophagy deficiency rather in-
creased the size of dopaminergic synaptic
terminal profiles and striatal dopaminergic in-
nervation, consistent with studies that implicatemacroautophagy in retraction of neuronal processes (Bunge,
1973) and neuritic growth in developing neurons (Hollenbeck,
1993). The results, however, contrast with studies in Drosophila,
in which disruption of AV formation or AV-lysosomal fusion
decreases the size of the neuromuscular junction, whereas
Atg1 overexpression or rapamycin promotes macroautophagy
and increases the number of synaptic boutons and neuritic
branches (Shen and Ganetzky, 2009). Some synaptic Atg1-
related changes may be autophagy independent because the
loss of other autophagy-related proteins does not mimic the
effect of Atg1 overexpression on the number of boutons and
neurite branches (Toda et al., 2008; Wairkar et al., 2009).
We further observed that chronic Atg7 deficiency in dopamine
terminals led to an increase in presynaptic mitochondria (data
not shown); Atg7 deficiency may contribute to changes in mito-
chondria in multiple ways, for example, via effects on presyn-
aptic mitochondria size, shape, trafficking, fission, and fusion.
Autophagy Induction and Synaptic Vesicles
Acute induction of AVs by rapamycin in control neurons was
confirmed by electron microscopy, LC3 immunolabel, and
transiently elevated LC3-II. Acute exposure to rapamycin
decreased synaptic terminal profile size and number of synaptic
vesicles, indicating that mTOR inhibition can rapidly decrease
presynaptic components. SomeAV-like profiles contained cargo
that resembled synaptic vesicles, although we were unable to
immunolabel AV components, presumably due to the low luminal
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Presynaptic MacroautophagypH. Presynaptic terminals are very active in endocytosis due to
the turnover and recycling of synaptic vesicles, receptors, and
other constituents, and it is likely that many of the multilamellar
organelles we observe are products of the fusion of endosomes
and AVs, sometimes called ‘‘amphisomes.’’ An apparently clear
content of occasional AV-like organelles suggests that acute
mTOR blockade may result in some ‘‘empty’’ early AVs (Marti-
nez-Vicente et al., 2010).
AV-like profiles were absent in dopamine axon profiles of
the Atg7-deficient mice, and although low levels of LC3-immu-
nolabeled puncta were present in the mutant neurons, they
were not enhanced by rapamycin. Thus, the increase in AVs by
mTOR inhibition apparently requires Atg7, and we hypothesize
that, in normal neurons, rapamycin redistributed synaptic vesicle
membranes into axonal AVs, endosomes, and/or amphisomes.
Synaptic Transmission in Atg7 DAT Cre Animals
Chronic lack of macroautophagy enhanced evoked dopamine
release and the rate of synaptic recovery. At a variety of
synapses, a higher release probability can increase the peak
amplitude from the first pulse followed by a relative depression
from the second pulse, due to a decreased availability of
release-ready vesicles, culminating in a lower paired-pulse ratio
(second pulse/first pulse). This situation differs from that in Atg7
DAT Cre animals, in which both the initial and subsequent pulses
showed increased amplitudes relative to control mice. The prob-
ability of dopaminergic synaptic vesicle fusion is regulated by the
size of the recycling and readily releasable pools (Daniel et al.,
2009): the enhanced release and recovery in the mutant line
could be due tomultiple nonexclusive effects, including a greater
synaptic terminal size or density, a greater number of synaptic
vesicles, more calcium influx, or an increase in vesicle docking
and fusion sites and/or rates. We measured lower total striatal
DAT and TH levels in the macroautophagy-deficient line,
although the kinetics of dopamine release do not indicate altered
activity of the proteins, which are regulated by a variety of
compensatory mechanisms (Schmitz et al., 2003).
Rapamycin depressed evoked dopamine release in control
mice but had no effect in Atg7 DAT Cre mice, confirming that
the rapid changes in neurotransmission evoked by mTOR
inhibtion were macroautophagy dependent and not the result
of effects on protein synthesis.
Although we have focused on dopaminergic terminals, the
data suggest that these effects are not specific to them. Rapa-
mycin induced apparent AVs in both dopaminergic (TH+) and
nondopaminergic (TH) terminals, and a decrease in synaptic
vesicles was observed generally in striatal synaptic terminals,
which include glutamatergic, dopaminergic, GABAergic, and
cholinergic synaptic terminals. Our experiments do not address
how subsets of particular presynaptic organelles, such as
individual synaptic vesicles, may be specifically targeted by
mTOR-dependent axonal macroautophagy. Clues might be
offered if alternative modes of vesicle recycling are identified
that could partake in or avoid endocytic compartments that
might fuse with AVs (Voglmaier et al., 2006).
Starvation, injury, oxidative stress, toxins, including metham-
phetamine, and infection by neurotropic viruses trigger autoph-
agy in neurons, which is further associated with proteinaggregate-related disorders, including Huntington’s, Parkin-
son’s, and Alzheimer’s diseases (Cheng et al., 2011; Koga
et al., 2011; Larsen et al., 2002; Tallo´czy et al., 2002; Tooze
and Schiavo, 2008). mTOR activity is regulated by multiple
endogenous pathways involved in synaptic activity and stress,
including tuberous sclerosis complex, Rheb, AKT, NF1, and
PTEN (Malagelada et al., 2010). Alterations in mTOR activity
are associated with neuropathological conditions such as
epilepsy, tuberous sclerosis, and autism. Regulation of pre-
synaptic function by mTOR activity and macroautophagy could
thus contribute to manifestations of neurological disorders.
EXPERIMENTAL PROCEDURES
Details of the experimental procedures can be found in the Supplemental
Experimental Procedures.
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